Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study). (July 2022)

• Record Type: Journal Article
• Authors: Tsubata, Yukari; Hotta, Takamasa; Hamai, Kosuke; Furuya, Naoki; Yokoyama, Toshihide; Saito, Ryota; Nakamura, Atsushi; Masuda, Takeshi; Hamaguchi, Megumi; Kuyama, Shoichi; Honda, Ryoichi; Senoo, Tadashi; Nakanishi, Masamoto; Yamasaki, Masahiro; Ishikawa, Nobuhisa; Fujitaka, Kazunori; Kubota, Tetsuya; Ohtsu, Hiroshi; Kobayashi, Kunihiko; Isobe, Takeshi
• Is Part Of: Therapeutic advances in medical oncology. Volume 14(2022)
• Publication Date: 2022-07
• Subjects: anticoagulants -- cancer -- lung neoplasms -- pulmonary embolism -- venous thromboembolism -- venous thrombosis; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/17588359221110171
• Languages: English
• ISSNs: 1758-8340

Abstract

Background: Venous thromboembolism (VTE) is a well-known type of cancer-associated thrombosis and a common complication of malignancy. However, the incidence of VTE associated with lung cancer and the effectiveness of direct oral anticoagulants remain unclear. This study aimed to identify the incidence of VTE associated with lung cancer at the time of diagnosis or during treatment, the efficacy and safety of edoxaban, and associated risk factors. Methods: The Rising-VTE/NEJ037 study was a multicenter prospective observational study. Altogether, 1021 patients with lung cancer who were unsuitable for radical resection or radiation were enrolled and followed up for 2 years. Patients with VTE at the time of lung cancer diagnosis started treatment with edoxaban. The primary endpoint of this trial was the rate of newly diagnosed VTE after enrollment or recurrence rate 6 months after treatment initiation. Results: Data were available for 1008 patients. The median age was 70 years (range: 30–94 years), and 70.8% were men. Sixty-two patients had VTE at the time of lung cancer diagnosis, and 38 (9.9%) developed VTE at follow-up. No cases of VTE recurrence were recorded 6 months after treatment initiation with edoxaban. Major and clinically relevant non-major bleeding events occurred in 4.9% of patients and increased to 22.7% in the edoxaban treatment group. Conclusions: VTE occurrence should be monitored during lung cancer treatment. Although treatment with edoxaban was highly effective in preventing VTE recurrence, its administration should be cautiously considered because of the high bleeding rate. Trial registration: jRCTs061180025.